Skip to main content
Move the World.
antibody inhaler

Lead Image © Natthakit / Adobe Stock

The race to develop a safe and effective COVID-19 vaccine may be the biggest scientific effort of our lifetime, but even with more and more potential vaccines creeping toward clinical use, it may be a while until everyone is able to receive these critical vaccinations.

In the meantime, scientists are working to develop treatments for the disease that may help protect high-risk communities before covid vaccinations become widespread.

A new antibody-based treatment, recently presented in the journal Cell, could not only help treat symptoms in those already infected but could also potentially prevent new infections from occurring (temporarily, at least).

While this antibody therapy has currently just been demonstrated in two animal models, mice and hamsters, if it also works in humans, it could potentially be delivered just like an inhaler for asthma, rapidly coating the lungs with virus-neutralizing antibodies.

A Short-Term Solution

When it comes to treating infectious viral diseases, a vaccine is the gold standard: if you never get it, you'll never die from it. But it's not the only option.

For COVID-19 in particular, antibody therapies have caught the attention of scientists as a way to fight existing covid infections. These therapies differ from vaccines in a few key ways.

The antibodies could be delivered just like an inhaler for asthma.

Vaccines work by introducing a small part of the virus to your system and training your body to create antibodies (defense proteins) to fight off the virus. Then, if you're ever actually infected with the live virus, your body knows exactly what to do to stop it. Vaccines are generally designed to work for years but may be topped up occasionally with booster shots.

Antibody therapies, on the other hand, fight disease by injecting antibodies into your body directly, instead of waiting for your immune system to make them itself.

These antibodies can come from the blood of previous survivors or from certain animals (like horses or alpacas), or they can be cloned and manufactured in a laboratory. Antibody infusions can be useful if somebody is already sick and their immune system needs reinforcements, or they can provide short-term immunity if there is no vaccine available yet.

Because your body isn't actually producing the antibodies, though, your system will clear them out as soon as you stop taking the treatment, so this isn't a long-term solution, but it can provide temporary relief and protection.

Needle in an Antibody Haystack

But before the researchers could begin testing an antibody therapy, they first had to go fishing to find an antibody that would work for SARS-CoV-2, the virus that causes COVID-19.

To do this the researchers sifted through catalogs of 100 billion potential antibodies made from human blood samples and "baited" antibodies with a piece of the SARS-CoV-2 virus – its signature spike protein. In record time, they were able to zero-in on a super tiny, but effective antibody. When the smallest part of the antibody is fused together with its own tail, it formed the light-weight drug Ab8, which the researchers say has the full immune-boosting power of a regular sized antibody, without all the extra weight.

The drug was tested on a mouse that had been infected with a modified SARS-CoV-2 virus, and the researchers found that very small doses of the drug were able to decrease the amount of virus in the mouse by 90%. This worked in part because Ab8 is able to bind to the coronavirus and prevent it from attaching to cells.

They also found that preemptively administering small doses of the drug to hamsters successfully prevented infection when they were later exposed to the virus, similar to what a vaccine might do.

The scientists behind the study also noted that because Ab8 is so lightweight, it could potentially be delivered by inhaling a mist or vapor straight into the lungs (the preferred target of SARS-CoV-2). This could potentially increase its efficacy and ease of use compared to an intravenous solution, which generally has to be administered in a hospital.

This drug has now been licensed by the biotechnology company Abound Bio for worldwide development. The researchers hope to begin human testing and safety trials of the drug in 2021.

What's Next

While the results of this study are promising, that does not mean the drug will be cheap or easy to manufacture and distribute. And this steep cost may work to limit access to these drugs in some parts of the world, especially poorer countries.

As this drug heads into human testing, we will better know how accessible a solution like this might truly be.

Up Next

If you want to understand a problem, talk to the people working on solutions. Join us as we meet the people and explore the ideas on the frontlines of an unprecedented global response.

Coronavirus
Coronavirus Nasal Spray Vaccine Nears Human Trials
Coronavirus Nasal Spray Vaccine
Coronavirus
Coronavirus Nasal Spray Vaccine Nears Human Trials
A nasal spray vaccine for COVID-19 that contains a live coronavirus genetically engineered to replicate more slowly is nearing human trials.

A nasal spray vaccine for COVID-19 that contains a live coronavirus genetically engineered to replicate more slowly is nearing human trials.

Coronavirus
Robots Are Running COVID-19 Drug Development
COVID-19 Drug Development
Coronavirus
Robots Are Running COVID-19 Drug Development
IBM’s new online platform, RoboRXN, combines artificial intelligence, cloud computing, and robotics to automate the COVID-19 drug development process.

IBM’s new online platform, RoboRXN, combines artificial intelligence, cloud computing, and robotics to automate the COVID-19 drug development process.

Coronavirus
Updated Coronavirus Vaccine List: Where We Stand Today
Coronavirus Vaccine List
Coronavirus
Updated Coronavirus Vaccine List: Where We Stand Today
A regularly updated coronavirus vaccine list highlighting the candidates closest to receiving approval from regulators.

A regularly updated coronavirus vaccine list highlighting the candidates closest to receiving approval from regulators.

Coronavirus
What We Know About How the Coronavirus Affects the Brain
Coronavirus Affects the Brain
Coronavirus
What We Know About How the Coronavirus Affects the Brain
Studies are finding that the coronavirus affects the brain as well as the lungs in some patients, causing delirium, strokes, and even fatal swelling.

Studies are finding that the coronavirus affects the brain as well as the lungs in some patients, causing delirium, strokes, and even fatal swelling.

Public Health
Cheap CRISPR-Based Coronavirus Test Delivers Fast Results
CRISPR-Based Coronavirus Test
Public Health
Cheap CRISPR-Based Coronavirus Test Delivers Fast Results
Scientists have unveiled STOPCovid, a CRISPR-based coronavirus test that avoids many of the shortcomings of existing diagnostic tests.

Scientists have unveiled STOPCovid, a CRISPR-based coronavirus test that avoids many of the shortcomings of existing diagnostic tests.

Public Health
FDA Authorizes First At-Home Coronavirus Test Kit
At-Home Coronavirus Test
Public Health
FDA Authorizes First At-Home Coronavirus Test Kit
The FDA has authorized LabCorp’s at-home coronavirus test kit, meaning people no longer need to leave their houses to find out if they have COVID-19.

The FDA has authorized LabCorp’s at-home coronavirus test kit, meaning people no longer need to leave their houses to find out if they have COVID-19.

Public Health
Scientists Find a Way to Quickly ID Coronavirus Mutations
coronavirus mutations
Public Health
Scientists Find a Way to Quickly ID Coronavirus Mutations
A new tool that allows scientists to quickly identify coronavirus mutations could help experts track and treat COVID-19.

A new tool that allows scientists to quickly identify coronavirus mutations could help experts track and treat COVID-19.

Public Health
Plasma from Coronavirus Survivors Helps Sick Patients Recover
Plasma from Coronavirus Survivors
Public Health
Plasma from Coronavirus Survivors Helps Sick Patients Recover
Two studies in China found that plasma from coronavirus survivors helps patients with severe cases of COVID-19 recover within days of treatment.

Two studies in China found that plasma from coronavirus survivors helps patients with severe cases of COVID-19 recover within days of treatment.

Healthcare
New Tool Seeks to Protect Those Reusing Coronavirus Masks
Coronavirus Masks
Healthcare
New Tool Seeks to Protect Those Reusing Coronavirus Masks
A group of researchers launched a website that teaches healthcare workers everything they need to know about reusing coronavirus masks as safely as possible.

A group of researchers launched a website that teaches healthcare workers everything they need to know about reusing coronavirus masks as safely as possible.